Rondo Therapeutics

Rondo Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of next-generation T-cell engaging bispecific antibodies for the treatment of solid tumors. The company's proprietary platform focuses on CD28 co-stimulation, designed to enhance and sustain T-cell activity within the tumor microenvironment while minimizing systemic toxicity. Founded by the leadership team behind Teneobio (acquired by Amgen), Rondo leverages deep expertise in antibody engineering to create 'signal 2' co-stimulatory molecules. These therapies aim to overcome the limitations of traditional T-cell engagers and antibody-drug conjugates (ADCs) in solid tumor indications such as bladder, ovarian, and renal cancers.